| 000 | 03778nam a22003257a 4500 | ||
|---|---|---|---|
| 001 | CUHAS/MMED/6000377/T/20 | ||
| 003 | CUHAS/MMED/6000377/T/20 | ||
| 005 | 20240613123904.0 | ||
| 008 | 231116b |||||||| |||| 00| 0 eng d | ||
| 028 | _bWurzburg Road 35, BMC Premises, Post Code: 33102: | ||
| 028 | _b P. O. Box 1464, Mwanza – Tanzania: | ||
| 028 | _b Phone: +255 28 298 3384: | ||
| 028 | _bFax: +255 28 298 3386: | ||
| 028 | _bEmail: vc@bugando.ac.tz: | ||
| 028 | _b www.bugando.ac.tz | ||
| 035 | _aCUHAS/MMED/6000377/T/20 | ||
| 040 |
_bEnglish _cDDC |
||
| 041 | _aEnglish | ||
| 082 | _a616 | ||
| 100 |
_d[Male] _eCUHAS/MMED/6000377/T/20 _q Nana Karim Aziz |
||
| 245 | _aPrevalence, Pattern and Associated Factors for Dyslipidemia Among HIV-Infected Patients on Dolutegravir Based First Line Antiretroviral Therapy Regimen Attending Bugando Medical Centre, Mwanza, Tanzania. | ||
| 260 |
_aMwanza, Tanzania: _bCatholic University of Health and Allied Sciences [CUHAS – Bugando] : _c2023 |
||
| 300 | _a120 Pages | ||
| 300 | _aIncludes References and Appendicies | ||
| 520 | _aAbstract: Background: The use of antiretroviral medication to treat HIV infection for a long time has been linked to dyslipidemia and subsequent cardiovascular diseases. People who are at a higher risk of cardiovascular disease may benefit from antiretroviral drugs with better lipid profiles. Dolutegravir (DTG) a newer Antiretroviral agent has been recommended to be used in combinations with dual nucleoside reverse transcriptase inhibitors. Little is known regarding the prevalence, pattern, and associated factors for dyslipidemia among People Living with HIV (PLWH) using DTG based c-ART. Objective: The objective was to determine the prevalence, pattern and associated factors for dyslipidemia among HIV-infected patients on dolutegravir based regimen attending CTCBMC. Methodology: This was Hospital based cross-sectional study with convenient sampling method was used to enroll a total of 374 PLWH on DTG based first line treatment conducted from May 2023 to June 2023 at BMC’s CTC clinic. A structured questionnaire was used to collect patients’ demographic and clinical information. Blood samples were collected for laboratory analysis. Dyslipidemia was defined by NCEP-ATP III, as at least one abnormality in lipid parameter among the following; TC > 5.17 mmol/l or TG > 1.7 mmol/l or HDL-c < 1.03 mmol/l or LDL-c > 3.36 mmol/l. Data was analyzed using STATA 13. Results: Among PLWH on DTG based first line regimens, 68.18% (255/374) had dyslipidemia. None of the study participants were on lipid lowering therapy. The most common pattern was single dyslipidemia which was low HDL-C at 43.9% (112/255) and the most common mixed dyslipidemia was high TC +high LDL-C at 13.7% (35/255) among all patients with dyslipidemia. Factors associated with dyslipidemia were age ≥ 55 years (OR 2.9 (1.5-5.8), P=0.02), office SBP ≥ 140mmHg (OR 2.0 (1.09-3.74), P=0.024), duration of DTG therapy >30-≤ 42 months (OR 6.4 (1.4-29.5), P=0.018), duration of DTG therapy > 42 months (OR 5.7 (1.3-23.6), P= 0.017), overweight (OR 2.7 (1.6-4.8), P=<0.001) and obesity (OR 4.1(1.7- 10.4),P=0.002). Conclusion: Our findings show a high prevalence of dyslipidemia among PLWH on DTG based therapies. The most prevalent type of dyslipidemia was single dyslipidemia of low HDLC. The use DTG ≥ 2 years and 6 months, age ≥ 55 years, elevated office SBP, overweight and obesity were associated factors for dyslipidemia Therefore, routine assessment of lipid profiles for targeted high-risk individuals is recommended. | ||
| 600 | _xInternal Medicine | ||
| 700 | _qSamuel Kalluvya | ||
| 700 | _qDesderius Bernard | ||
| 942 |
_2ddc _cMP _n1 |
||
| 999 |
_c18765 _d18765 |
||